Covered recipient · General Payments record
JAY H SANDBERG
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$5,202.68
117 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,172.30 | 110 |
| Consulting Fee | $2,136.00 | 1 |
| Travel and Lodging | $875.11 | 5 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19.27 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $3,483.74 | 21 |
| AstraZeneca Pharmaceuticals LP | $253.54 | 14 |
| Novo Nordisk Inc | $250.34 | 17 |
| Lilly USA, LLC | $236.35 | 15 |
| PFIZER INC. | $192.93 | 11 |
| Sumitomo Pharma America, Inc. | $112.75 | 6 |
| Merck Sharp & Dohme LLC | $97.00 | 4 |
| Abbott Laboratories | $87.89 | 4 |
| Astellas Pharma US Inc | $78.10 | 5 |
| Lundbeck LLC | $75.37 | 3 |
| AIMMUNE THERAPEUTICS, INC. | $72.43 | 4 |
| ABBVIE INC. | $63.89 | 3 |
| Exact Sciences Corporation | $52.44 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $48.98 | 3 |
| GlaxoSmithKline, LLC. | $23.25 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.17 | 1 |
| Otsuka America Pharmaceutical, Inc. | $19.89 | 1 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $18.45 | 1 |
| Esperion Therapeutics, Inc. | $15.17 | 1 |
Page 3 of 3; records 101–117 of 117 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAY H SANDBERG
NPI 1548293483 · CMS profile ID 206406
Allopathic & Osteopathic Physicians / Internal Medicine
TROY, MI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–117 of 117 matching records. This page contains 17 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1548293483?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAY H SANDBERG, NPI 1548293483, CMS profile ID 206406. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–117 of 117 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548293483?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). JAY H SANDBERG, NPI 1548293483, CMS profile ID 206406. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–117 of 117 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548293483?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- JAY H SANDBERG, NPI 1548293483, CMS profile ID 206406, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–117 of 117 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1548293483?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
117 matching records · $5,202.68 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–117 of 117.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $22.06 | 02/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125118460 | CMS |
| Novo Nordisk Inc | $13.65 | 02/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097628259 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.29 | 02/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104351554 | CMS |
| Novo Nordisk Inc | $6.56 | 02/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097272921 | CMS |
| Lilly USA, LLC | $18.21 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135033986 | CMS |
| ABBVIE INC. | $19.79 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106013135 | CMS |
| Lilly USA, LLC | $15.82 | 02/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135032898 | CMS |
| Amgen Inc. | $15.00 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117373512 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.20 | 01/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104629494 | CMS |
| Sumitomo Pharma America, Inc. | $16.03 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148914152 | CMS |
| PFIZER INC. | $19.77 | 01/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131068090 | CMS |
| AstraZeneca Pharmaceuticals LP | $37.77 | 01/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104332408 | CMS |
| Lilly USA, LLC | $14.53 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135055016 | CMS |
| Novo Nordisk Inc | $11.53 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097106160 | CMS |
| Lilly USA, LLC | $15.72 | 01/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135033378 | CMS |
| Lilly USA, LLC | $14.23 | 01/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135049048 | CMS |
| Amgen Inc. | $33.20 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111697332 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,509,593.96 | 142 |
| PY2024 | Principal investigator | $2,002,417.92 | 105 |
| PY2023 | Principal investigator | $1,345,098.03 | 83 |
| PY2022 | Principal investigator | $1,273,184.65 | 79 |
| PY2021 | Recipient | $138.20 | 1 |
| PY2021 | Principal investigator | $596,006.29 | 111 |
| PY2020 | Principal investigator | $137,699.34 | 45 |
| PY2019 | Principal investigator | $390,285.70 | 65 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
142 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $53,948.30 | 12/22/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226137247 |
| Principal investigator 1 | ModernaTX, Inc. | $805.84 | 12/19/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998249 |
| Principal investigator 1 | ModernaTX, Inc. | $4,861.56 | 12/19/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998261 |
| Principal investigator 1 | ModernaTX, Inc. | $59,094.75 | 12/19/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998273 |
| Principal investigator 1 | ModernaTX, Inc. | $2,880.00 | 12/19/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998279 |
| Principal investigator 1 | Genentech, Inc. | $8,000.00 | 12/17/2025 | Non-covered Recipient Entity JHSDOPC DBA OAKLAND MEDICAL RESEARCH | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211618314 |
| Principal investigator 1 | PFIZER INC. | $31,082.15 | 12/12/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228744446 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,917.90 | 12/08/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226137237 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220784583 |
| Principal investigator 1 | ModernaTX, Inc. | $4,320.00 | 11/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998207 |
| Principal investigator 1 | ModernaTX, Inc. | $5,435.76 | 11/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998229 |
| Principal investigator 1 | ModernaTX, Inc. | $2,417.52 | 11/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998259 |
| Principal investigator 1 | PFIZER INC. | $26,824.60 | 11/26/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228714320 |
| Principal investigator 1 | ModernaTX, Inc. | $715.00 | 11/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998237 |
| Principal investigator 1 | Genentech, Inc. | $7,614.00 | 11/21/2025 | Non-covered Recipient Entity OAKLAND MEDICAL RESEARCH CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211633252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 11/19/2025 | Non-covered Recipient Entity J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220784585 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 11/19/2025 | Non-covered Recipient Entity J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220784587 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,568.00 | 11/19/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234319 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $110,597.75 | 11/10/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226137196 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,460.00 | 11/07/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234237 |
| Principal investigator 1 | Genentech, Inc. | $25,295.00 | 11/04/2025 | Non-covered Recipient Entity OAKLAND MEDICAL RESEARCH CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211633248 |
| Principal investigator 1 | PFIZER INC. | $382.76 | 11/04/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228714318 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,042.00 | 11/03/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234276 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 11/01/2025 | Non-covered Recipient Entity J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220784575 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 11/01/2025 | Non-covered Recipient Entity J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220784577 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 11/01/2025 | Non-covered Recipient Entity J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220784579 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220784581 |
| Principal investigator 1 | PFIZER INC. | $79,566.30 | 10/31/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228740359 |
| Principal investigator 1 | ModernaTX, Inc. | $5,512.32 | 10/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998251 |
| Principal investigator 1 | ModernaTX, Inc. | $14,760.00 | 10/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998277 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $17,470.00 | 10/19/2025 | Non-covered Recipient Entity OAKLAND MEDICAL CENTER | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients | No dispute reported | 06/30/2026 | 1190306987 |
| Principal investigator 1 | PFIZER INC. | $8,309.28 | 10/08/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228755005 |
| Principal investigator 1 | ModernaTX, Inc. | $5,110.38 | 09/29/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998245 |
| Principal investigator 1 | ModernaTX, Inc. | $1,611.68 | 09/29/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998255 |
| Principal investigator 1 | ModernaTX, Inc. | $17,280.00 | 09/29/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998291 |
| Principal investigator 1 | PFIZER INC. | $1,913.80 | 09/24/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228751701 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,824.00 | 09/19/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234245 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,000.00 | 09/17/2025 | Non-covered Recipient Entity JHSDOPC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192113908 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,125.00 | 09/17/2025 | Non-covered Recipient Entity JHSDOPC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192113914 |
| Principal investigator 1 | PFIZER INC. | $13,351.80 | 09/03/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228749681 |
| Principal investigator 1 | PFIZER INC. | $1,913.80 | 09/03/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228753611 |
| Principal investigator 1 | ModernaTX, Inc. | $6,124.80 | 08/28/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998199 |
| Principal investigator 1 | ModernaTX, Inc. | $1,440.00 | 08/28/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998209 |
| Principal investigator 1 | ModernaTX, Inc. | $2,417.52 | 08/28/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998225 |
| Principal investigator 1 | ModernaTX, Inc. | $18,040.96 | 08/28/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998269 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,046.31 | 08/27/2025 | Non-covered Recipient Entity OAKLAND MEDICAL CENTER | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185543745 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,211.00 | 08/25/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234298 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $58,712.59 | 08/18/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226137654 |
| Principal investigator 1 | PFIZER INC. | $33,275.76 | 08/05/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228767412 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,951.40 | 08/04/2025 | Non-covered Recipient Entity Elias Research Associates LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226137637 |
| Principal investigator 1 | ModernaTX, Inc. | $1,569.48 | 07/28/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998219 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,806.00 | 07/23/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234268 |
| Principal investigator 1 | Genentech, Inc. | $5,622.00 | 07/22/2025 | Non-covered Recipient Entity OAKLAND MEDICAL RESEARCH CENTER | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211633244 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $73,376.39 | 07/21/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226137559 |
| Principal investigator 1 | PFIZER INC. | $56,042.00 | 07/17/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228772693 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $14,869.00 | 07/16/2025 | Non-covered Recipient Entity Oakland Medical Center | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic | No dispute reported | 06/30/2026 | 1225407356 |
| Principal investigator 1 | Genentech, Inc. | $9,269.00 | 07/02/2025 | Non-covered Recipient Entity JHSDOPC DBA OAKLAND MEDICAL RESEARCH | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211618309 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,488.70 | 07/02/2025 | Non-covered Recipient Entity Elias Research Associates LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226137568 |
| Principal investigator 1 | ModernaTX, Inc. | $8,640.00 | 06/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998221 |
| Principal investigator 1 | ModernaTX, Inc. | $4,363.92 | 06/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998253 |
| Principal investigator 1 | ModernaTX, Inc. | $47,357.52 | 06/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998257 |
| Principal investigator 1 | PFIZER INC. | $178,882.80 | 06/26/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228786930 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $17,672.58 | 06/24/2025 | Non-covered Recipient Entity Oakland Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease | No dispute reported | 06/30/2026 | 1235995032 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,676.00 | 06/23/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234254 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,884.00 | 06/20/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234221 |
| Principal investigator 1 | ModernaTX, Inc. | $58,633.12 | 06/18/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998211 |
| Principal investigator 1 | ModernaTX, Inc. | $4,842.42 | 06/18/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998287 |
| Principal investigator 1 | ModernaTX, Inc. | $16,560.00 | 06/18/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998289 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,409.85 | 06/16/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226137526 |
| Principal investigator 1 | Genentech, Inc. | $11,423.00 | 06/02/2025 | Non-covered Recipient Entity JHSDOPC DBA OAKLAND MEDICAL RE | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211618279 |
| Principal investigator 1 | PFIZER INC. | $18,784.00 | 05/30/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228763321 |
| Principal investigator 1 | ModernaTX, Inc. | $2,417.52 | 05/28/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998263 |
| Principal investigator 1 | ModernaTX, Inc. | $5,129.52 | 05/28/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998265 |
| Principal investigator 1 | ModernaTX, Inc. | $42,120.00 | 05/28/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998293 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,613.40 | 05/27/2025 | Non-covered Recipient Entity Elias Research Associates LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226137488 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,753.00 | 05/21/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234303 |
| Principal investigator 1 | PFIZER INC. | $2,283.94 | 05/21/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228771330 |
| Principal investigator 1 | PFIZER INC. | $15,947.74 | 05/19/2025 | Non-covered Recipient Entity Oakland Medical Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228706719 |
| Principal investigator 1 | PFIZER INC. | $15,947.74 | 05/19/2025 | Non-covered Recipient Entity Oakland Medical Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228762176 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $38,838.86 | 05/19/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226137544 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,120.00 | 05/16/2025 | Non-covered Recipient Entity OAKLAND MEDICAL CENTER | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185543747 |
| Principal investigator 1 | PFIZER INC. | $31,082.86 | 05/07/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228783251 |
| Principal investigator 1 | Genentech, Inc. | $846.00 | 05/06/2025 | Non-covered Recipient Entity JHSDOPC DBA OAKLAND MEDICAL RE | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211618270 |
| Principal investigator 1 | Genentech, Inc. | $3,003.00 | 05/06/2025 | Non-covered Recipient Entity JHSDOPC DBA OAKLAND MEDICAL RE | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211618274 |
| Principal investigator 1 | Genentech, Inc. | $1,964.00 | 04/30/2025 | Non-covered Recipient Entity JHSDOPC DBA OAKLAND MEDICAL RESEARCH | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211618305 |
| Principal investigator 1 | ModernaTX, Inc. | $9,720.00 | 04/28/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998223 |
| Principal investigator 1 | ModernaTX, Inc. | $1,339.80 | 04/28/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998227 |
| Principal investigator 1 | ModernaTX, Inc. | $25,560.00 | 04/28/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998281 |
| Principal investigator 1 | ModernaTX, Inc. | $3,904.56 | 04/28/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998285 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,506.00 | 04/23/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234261 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $28,766.70 | 04/21/2025 | Non-covered Recipient Entity Elias Research Associates LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226137440 |
| Principal investigator 1 | PFIZER INC. | $9,815.64 | 04/17/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228780185 |
| Principal investigator 1 | PFIZER INC. | $1,724.08 | 04/16/2025 | Non-covered Recipient Entity Oakland Medical Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228706721 |
| Principal investigator 1 | PFIZER INC. | $1,724.08 | 04/16/2025 | Non-covered Recipient Entity Oakland Medical Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228770890 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $41,809.31 | 04/14/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226137422 |
| Principal investigator 1 | PFIZER INC. | $6,896.32 | 04/09/2025 | Non-covered Recipient Entity Oakland Medical Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228706723 |
| Principal investigator 1 | PFIZER INC. | $6,896.32 | 04/09/2025 | Non-covered Recipient Entity Oakland Medical Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228761436 |
| Principal investigator 1 | PFIZER INC. | $10,344.48 | 04/08/2025 | Non-covered Recipient Entity Oakland Medical Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228708092 |
| Principal investigator 1 | PFIZER INC. | $10,344.48 | 04/08/2025 | Non-covered Recipient Entity Oakland Medical Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228760185 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,200.00 | 04/02/2025 | Non-covered Recipient Entity JHSDOPC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1192113919 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $34,496.80 | 04/02/2025 | Non-covered Recipient Entity JHSDOPC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1192113923 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,500.00 | 04/02/2025 | Non-covered Recipient Entity Elias Research Associates LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226137390 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,919.60 | 04/02/2025 | Non-covered Recipient Entity Elias Research Associates LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226137403 |
| Principal investigator 1 | Genentech, Inc. | $2,922.00 | 03/28/2025 | Non-covered Recipient Entity JHSDOPC DBA OAKLAND MEDICAL RESEARCH | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211618303 |
| Principal investigator 1 | ModernaTX, Inc. | $36,000.00 | 03/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998215 |
| Principal investigator 1 | ModernaTX, Inc. | $805.84 | 03/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998241 |
| Principal investigator 1 | ModernaTX, Inc. | $4,995.54 | 03/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998271 |
| Principal investigator 1 | ModernaTX, Inc. | $15,595.58 | 03/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998275 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $65,608.15 | 03/24/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226137339 |
| Principal investigator 1 | Genentech, Inc. | $1,964.00 | 03/21/2025 | Non-covered Recipient Entity JHSDOPC DBA OAKLAND MEDICAL RESEARCH | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211618295 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,299.00 | 03/21/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234229 |
| Principal investigator 1 | PFIZER INC. | $677.05 | 03/18/2025 | Non-covered Recipient Entity Oakland Medical Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228774726 |
| Principal investigator 1 | PFIZER INC. | $793.65 | 03/18/2025 | Non-covered Recipient Entity Oakland Medical Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228786067 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,044.00 | 03/17/2025 | Non-covered Recipient Entity J H S D O P C | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175362613 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $67,656.12 | 03/10/2025 | Non-covered Recipient Entity OAKLAND MEDICAL RESEARCH CENTER | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients | No dispute reported | 06/30/2026 | 1190306989 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,134.54 | 03/08/2025 | Non-covered Recipient Entity OAKLAND MEDICAL RESEARCH | A PHASE 3, MULTICENTER, LONG-TERM, EXTENSION STUDY OF THE SAFETY AND EFFICACY OF AVP-786 (DEUTERATED [D6] DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | No dispute reported | 06/30/2026 | 1225335659 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $64,457.50 | 03/04/2025 | Non-covered Recipient Entity Elias Research Associates LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226137401 |
| Principal investigator 1 | Genentech, Inc. | $2,895.00 | 03/03/2025 | Non-covered Recipient Entity OAKLAND MEDICAL RESEARCH CENTER | Transmission Study household | No dispute reported | 06/30/2026 | 1211633240 |
| Principal investigator 1 | Genentech, Inc. | $9,748.00 | 02/28/2025 | Non-covered Recipient Entity JHSDOPC DBA OAKLAND MEDICAL RESEARCH | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211618286 |
| Principal investigator 1 | ModernaTX, Inc. | $39,799.08 | 02/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998197 |
| Principal investigator 1 | ModernaTX, Inc. | $2,417.52 | 02/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998231 |
| Principal investigator 1 | ModernaTX, Inc. | $5,799.42 | 02/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998243 |
| Principal investigator 1 | ModernaTX, Inc. | $49,014.68 | 02/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998247 |
| Principal investigator 1 | ModernaTX, Inc. | $2,717.88 | 02/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998267 |
| Principal investigator 1 | ModernaTX, Inc. | $25,560.00 | 02/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998297 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,117.00 | 02/19/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234313 |
| Principal investigator 1 | PFIZER INC. | $6,886.50 | 02/12/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228768941 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,357.01 | 02/10/2025 | Non-covered Recipient Entity Elias Research Associates LLC | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226137317 |
| Principal investigator 1 | Genentech, Inc. | $982.00 | 02/05/2025 | Non-covered Recipient Entity JHSDOPC DBA OAKLAND MEDICAL RESEARCH | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211618299 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $41,737.70 | 02/04/2025 | Non-covered Recipient Entity Elias Research Associates LLC | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226137288 |
| Principal investigator 1 | ModernaTX, Inc. | $4,287.36 | 01/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998195 |
| Principal investigator 1 | ModernaTX, Inc. | $2,417.52 | 01/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998201 |
| Principal investigator 1 | ModernaTX, Inc. | $1,722.60 | 01/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998203 |
| Principal investigator 1 | ModernaTX, Inc. | $42,330.86 | 01/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998205 |
| Principal investigator 1 | ModernaTX, Inc. | $2,430.78 | 01/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998213 |
| Principal investigator 1 | ModernaTX, Inc. | $1,080.00 | 01/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998217 |
| Principal investigator 1 | ModernaTX, Inc. | $86,231.34 | 01/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998233 |
| Principal investigator 1 | ModernaTX, Inc. | $49,748.85 | 01/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998235 |
| Principal investigator 1 | ModernaTX, Inc. | $5,512.32 | 01/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998239 |
| Principal investigator 1 | ModernaTX, Inc. | $14,400.00 | 01/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998283 |
| Principal investigator 1 | ModernaTX, Inc. | $17,823.52 | 01/27/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252998295 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,013.00 | 01/22/2025 | Non-covered Recipient Entity Jhsdopc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175234288 |